Psoriatic arthritis and TNF inhibitors: advances on effectiveness and toxicity.

Over the last decade, due to the high expectations that biologic drugs like anti-TNF are raising, the appropriate identification of patients eligible for these treatments has been conditioned by numerous ordinary aspects, mainly represented by previous or ongoing comorbidities and related therapies, and chronic infections or recurrence of acute infections. Additionally, in the last years, due to close monitoring by experienced clinicians, remarkable changes have been also obtained in the field of safety. Another question mark refers to the management of psoriatic arthritis systemic manifestations, in which the impact of biologic therapy is not enough explored.